Search Results

Basilea Pharmaceutica Ltd announced that it has entered into an asset purchase agreement with the Glioblastoma Foundation Inc., for Basilea’s oncology drug candidate lisavanbulin, which has been developed as a potential therapy for glioblastoma, the most common type of primary brain cancer.

Basilea Pharmaceutica Ltd. announced that the continued strong sales performance of the antifungal Cresemba® by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment.

Basilea Pharmaceutica Ltd announced that it has been awarded a grant from CARB-X, a global non-profit partnership dedicated to supporting the early development of antibacterial products.

Basilea Pharmaceutica received FDA approval for its antibiotic Zevtera in three indications Wednesday, finally getting the drug across the finish line a decade and a half after the agency rejected an earlier submission.

Basilea Pharmaceutica Ltd announced that scientific presentations with new data on its antibiotic ceftobiprole have been presented at ESCMID Global 2024, the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, which took place from April 27 to 30, 2024 in Barcelona, Spain.

Basilea Pharmaceutica Ltd announced its results for the financial year ended December 31, 2023.

Basilea Pharmaceutica Ltd reported on the progress within its R&D portfolio in 2023 and upcoming milestones and timelines.

Basilea Pharmaceutica Ltd, Allschwil announced that the US Food and Drug Administration approved ZEVTERA®, for the treatment of adult patients with Staphylococcus aureus bloodstream infections, including those with right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections and for adult and pediatric patients with community-acquired bacterial pneumonia.

Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that it will accelerate the repayment of its senior secured loan.

Basilea Pharmaceutica Ltd announced that it has entered into an asset purchase agreement with Spexis AG for a preclinical program of antibiotics from a novel class, targeting Gram-negative bacteria, including multidrug-resistant strains.